Adenovirus: Current epidemiology and emerging approaches to prevention and treatment

Current Infectious Disease Reports

Volumn 16, Issue 8, 2014, Pages

  Sandkovsky, Uriel ^a   Vargas, Luciano ^b   Florescu, Diana F ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Bone marrow transplant; Hematopoietic stem cell transplant; Solid organ transplantation

Indexed keywords

BRINCIDOFOVIR; CIDOFOVIR; GANCICLOVIR; PROBENECID; RIBAVIRIN;

ADENOVIRUS; ADENOVIRUS INFECTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; BONE MARROW TOXICITY; CLINICAL FEATURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FLUID THERAPY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTESTINE TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTE TRANSFUSION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; RECOMMENDED DRUG DOSE; RISK FACTOR; SEROTYPE; T LYMPHOCYTE; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

EID: 84901881172     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0416-y     Document Type: Article

References (86)

1. Ruuskanen O, Meurman O, Akusjärvi G. Adenoviruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. Washington, DC: ASM Press; 2002. p. 515-35.
2. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21(4):704-15.
3. Hoffman JA. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant. 2009;14(6):625-33.
4. •• Florescu DF, Hoffman JA. Adenovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:206-11.
5. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol. 2002;76(21):10608-16. (Pubitemid 35176177)
6. •• Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555-63.
7. Mori Y, Miyamoto T, Kamezaki K, et al. Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era. Am J Hematol. 2012;87(8):828-30.
8. Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol Immunol. 2009;47(1):46-51.
9. Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341-52. (Pubitemid 38351819)
10. Kohno K, Nagafuji K, Tsukamoto H, et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis. 2009;11(4):318-23.
11. Blanke C, Clark C, Broun ER, et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am J Med. 1995;99(3):326-8.
12. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32(9):1290-7. (Pubitemid 32405900)
13. Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet. 2001;358(9279):384-5. (Pubitemid 32739102)
14. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169(4):775-81. (Pubitemid 24102109)
15. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;23(3):277-82. (Pubitemid 29078342)
16. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(7):388-94. (Pubitemid 32799057)
17. Howard DS, Phillips IG, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29(6):1494-501. (Pubitemid 30022747)
18. Kalpoe JS, van der Heiden PL, Barge RM, et al. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. Eur J Haematol. 2007;78(4):314-21. (Pubitemid 46365085)
19. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol. 2005;130(4):595-603. (Pubitemid 43899764)
20. Kroes AC, de Klerk EP, Lankester AC, et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol. 2007;38(4):341-7. (Pubitemid 46413997)
21. La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32(6):871-6. (Pubitemid 32524820)
22. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis. 2004;38(1):45-52. (Pubitemid 38045872)
23. Ljungman P, Gleaves CA, Meyers JD. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant. 1989;4(1):35-40. (Pubitemid 19064904)
24. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. New Engl J Med. 1985;312(9):529-33. (Pubitemid 15174147)
25. van Tol MJ, Claas EC, Heemskerk B, et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant. 2005;35 Suppl 1:S73-6. (Pubitemid 40613928)
26. Venard V, Carret A, Corsaro D, Bordigoni P, Le Faou A. Genotyping of adenoviruses isolated in an outbreak in a bone marrow transplant unit shows that diverse strains are involved. J Hosp Infect. 2000;44(1):71-4. (Pubitemid 30074339)
27. Wasserman R, August CS, Plotkin SA. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J. 1988;7(2):109-15. (Pubitemid 18064627)
28. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006;81(10):1398-404. (Pubitemid 43847149)
29. Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 2000;26(12):1333-8. (Pubitemid 32098053)
30. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100(5):1619-27. (Pubitemid 34925137)
31. Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis. 2007;45(8):958-65. (Pubitemid 47580342)
32. Ganzenmueller T, Buchholz S, Harste G, Dammann E, Trenschel R, Heim A. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. J Clin Virol. 2011;52(1):55-9.
33. Gustafson I, Lindblom A, Yun Z, et al. Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients. J Clin Virol. 2008;43(1):79-85.
34. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102(3):1114-20. (Pubitemid 36917814)
35. Lion T, Kosulin K, Landlinger C, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia. 2010;24(4):706-14.
36. Schilham MW, Claas EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis. 2002;35(5):526-32.
37. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;10(3):186-94. (Pubitemid 38262881)
38. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36(11):1001-8. (Pubitemid 41741564)
39. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis. 1998;177(2):459-62. (Pubitemid 28063775)
40. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):170-4.
41. de Mezerville MH, Tellier R, Richardson S, Hebert D, Doyle J, Allen U. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr Infect Dis J. 2006;25(9):815-8. (Pubitemid 44325784)
42. Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116(4):617-23. (Pubitemid 28460628)
43. Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007;26(9):883-9. (Pubitemid 47376820)
44. Liu M, Mallory GB, Schecter MG, et al. Long-term impact of respiratory viral infection after pediatric lung transplantation. Pediatr Transplant. 2010;14(3):431-6.
45. Liu M, Worley S, Arrigain S, et al. Respiratory viral infections within one year after pediatric lung transplant. Transplant Infect Dis. 2009;11(4):304-12.
46. Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol. 1995;26(10):1073-9.
47. Humar A, Doucette K, Kumar D, et al. Assessment of adenovirus infection in adult lung transplant recipients usingmolecular surveillance. J Heart Lung Transplant. 2006;25(12):1441-6. (Pubitemid 44909466)
48. Florescu DF, Kwon JY, Dumitru I. Adenovirus infections in heart transplantation. Cardiol Rev. 2013;21(4):203-6.
49. Watcharananan SP, Avery R, Ingsathit A, et al. Adenovirus disease after kidney transplantation: course of infection and outcome in relation to blood viral load and immune recovery. Am J Transplant. 2011;11(6):1308-14.
50. Engelmann G, Heim A, Greil J, et al. Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transplant. 2009;13(4):421-8.
51. Koneru B, Jaffe R, Esquivel CO, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA. 1987;258(4):489-92. (Pubitemid 17096178)
52. McLaughlin GE, Delis S, Kashimawo L, et al. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR. Am J Transplant. 2003;3(2):224-8. (Pubitemid 36323120)
53. Florescu DF, Islam MK, Mercer DF, et al. Adenovirus infections in pediatric small bowel transplant recipients. Transplantation. 2010;90(2):198-204.
54. Parizhskaya M, Walpusk J, Mazariegos G, Jaffe R. Enteric adenovirus infection in pediatric small bowel transplant recipients. Pediatr Dev Pathol. 2001;4(2):122-8. (Pubitemid 32154969)
55. Pinchoff RJ, Kaufman SS, Magid MS, et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation. 2003;76(1):183-9. (Pubitemid 36877134)
56. Berho M, Torroella M, Viciana A, et al. Adenovirus enterocolitis in human small bowel transplants. Pediatr Transplant. 1998;2(4):277-82. (Pubitemid 128539691)
57. Gabriel R, Selwyn S, Brown D, et al. Virus infections and acute renal transplant rejection. Nephron. 1976;16(4):282-6.
58. Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. New Engl J Med. 2001;344(20):1498-503. (Pubitemid 32429208)
59. Florescu DF, Langnas AN, Sandkovsky U. Opportunistic viral infections in intestinal transplantation. Expert Rev Anti Infect Ther. 2013;11(4):367-81.
60. Florescu MC, Miles CD, Florescu DF. What do we know about adenovirus in renal transplantation? Nephrol Dial Transplant. 2013;28(8):2003-10.
61. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc. 2004;36(10):3025-7. (Pubitemid 41126732)
62. Moulik M, Breinholt JP, Dreyer WJ, et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol. 2010;56(7):582-92.
63. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol. 2003;13(3):155-71. (Pubitemid 36566085)
64. Ziring D, Tran R, Edelstein S, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation. 2005;79(6):702-9. (Pubitemid 40463177)
65. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43(3):331-9. (Pubitemid 44078906)
66. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005;5(10):2555-9.
67. Matthes-Martin S, Boztug H, Lion T. Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert Rev Anti Infect Ther. 2013;11(10):1017-28.
68. Seidemann K, Heim A, Pfister ED, et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant. 2004;4(12):2102-8. (Pubitemid 39611640)
69. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory Committee. Guideline for Isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 Suppl 2):S65-164.
70. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005;10(2):225-9. (Pubitemid 41151028)
71. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005;49(3):1010-6. (Pubitemid 40327717)
72. Asano-Mori Y, Kanda Y, Oshima K, et al. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother. 2006;57(5):1004-7.
73. Gilead. Vistide® (cidofovir injection). Foster City, CA: Gilead. 2000. http://www.gilead.com/pdf/vistide.pdf. Accessed 19 May 2014.
74. Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S161-5.
75. Hoffman JA. Adenoviral disease in pediatric solid organ transplant recipients. Pediatr Transplant. 2006;10(1):17-25.
76. Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A. 2008;105(20):7293-7. (Pubitemid 351754471)
77. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56(5):2726-34.
78. Grimley M, Chemaly R, Englund J, et al. The first interventional trial for adenovirus (AdV): brincidofovir (CMX001) for AdV in HCT. Proceedings of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10-13 September 2013; Denver, CO. Abstract T-351a.
79. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. New Engl J Med. 2013;369(13):1227-36.
80. Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18(5):731-8.
81. Grimley M, Papanicolaou G, Prasad V, et al. CMX001 is a potential treatment for adenovirus infection: preliminary antiviral activity results from an open-label, expanded access study of CMX001 for the treatment of serious or life-threatening diseases caused by double stranded DNA viruses. Proceedings of the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation; 7-10 April 2013; London, UK. Abstract 367.
82. Grimley M, Prasad V, Kurtzberg J, et al. Twice-weekly brincidofovir (CMX001) shows promising antiviral activity in immunocompromised transplant recipients with asymptomatic adenovirus viremia. Proceedings of the 2014 BMT Tandem Meetings; 26 February-2 March 2014; Grapevine (Dallas), TX. Oral abstract 105.
83. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64-76. (Pubitemid 43830030)
84. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283-92.
85. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113-23.
86. Kneidinger D, Ibrisimovic M, Lion T, Klein R. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res. 2012;94(3):195-207.